Data / Form D filings / Intrommune Therapeutics, Inc.
Intrommune Therapeutics, Inc.: Form D filings
Intrommune Therapeutics, Inc., a biotechnology company in New York, NY, filed 5 Form D notices with the SEC between 2018 and 2024. The latest, on January 22, 2024, reports $210,000 sold of a $10 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 20 W 125TH ST. UNIT #1, New York, NY, 10027
- Phone
- (646) 494-8432
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1736977
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 22, 2024 | New notice | $10,000,000 | $210,000 | $9,790,000 | 7 | Dec 6, 2023 | sec.gov |
| Jan 22, 2024 | New notice | $3,278,840 | $3,278,840 | 15 | Mar 16, 2022 | sec.gov | |
| Jul 8, 2021 | Amendment | $20,000,000 | $68,043 | $19,931,957 | 6 | Jul 2, 2021 | sec.gov |
| Jun 23, 2021 | New notice | $20,000,000 | $0 | $20,000,000 | 0 | Yet to occur | sec.gov |
| Apr 12, 2018 | New notice | $2,000,100 | $0 | $2,000,100 | 0 | Apr 12, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan Rich | Director | |
| William Reisacher | Director | |
| Michael Nelson | Executive Officer, Director | |
| Hemanshu Pandya | Director | |
| Erick Berglund | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Jan 22, 2024 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Intrommune Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.